Engineered immune cells take aim at tough childhood leukemias

NCT ID NCT04318678

First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 27 times

Summary

This early-phase trial tests a new treatment called CD123-CAR T cells for children and young adults up to age 21 with certain blood cancers (AML, MDS, ALL, or BPDCN) that have come back or not responded to standard therapy. The treatment involves collecting the patient's own immune cells, engineering them to target the CD123 protein on cancer cells, and giving them back after chemotherapy. The main goal is to find the safest dose and watch for side effects, while also checking if the cells can fight the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-ALL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • St Jude Children's Research Hospital

    RECRUITING

    Memphis, Tennessee, 38105, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • St. Jude Children's Research Hospital

    RECRUITING

    Memphis, Tennessee, 38105, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.